<DOC>
	<DOCNO>NCT01332955</DOCNO>
	<brief_summary>This phase II , multicentric , national pilot trial design estimate sustain virological response rate ( SVR ) follow 12 week treatment telaprevir combine 48 72 week treatment peginterferon ribavirin , base upon rapid virological response ( RVR ) week 8 ( 4 week telaprevir start ) , compare observe SVR 20 % , rate determine significant therapeutic benefit population patient . The primary endpoint SVR define undetectable HCV-RNA measure 24 week end therapy ( EOT ) .</brief_summary>
	<brief_title>Telaprevir HIV-HCV Coinfected Patients Who Had Previously Failed Peginterferon-Ribavirin Regimen</brief_title>
	<detailed_description>This phase II pilot trial design HIV-1 HCV genotype 1 coinfected patient previously fail peginterferon-ribavirin regimen . Intervention Design : - Induction , Lead-in , phase : day 0 week 4 PegInterferon alpha-2a , 180 µg subcutaneous injection , weekly + Ribavirin ( weight-based dose ) 1000 mg subject weigh &lt; 75 kg 1200 mg subject weigh ≥75 kg , b.i.d . - Telaprevir phase : week 4 week 16 PegInterferon alpha-2a , 180 µg subcutaneous injection , weekly + Ribavirin ( weight-based dose ) 1000 mg subject weigh &lt; 75 kg 1200 mg subject weigh ≥75 kg , b.i.d . + Telaprevir 750 mg q 8h ( 1125 mg q 8h association Efavirenz ) - Maintenance phase : week 16 week 48 72 PegInterferon alpha-2a , 180 µg subcutaneous injection , weekly + Ribavirin ( weight-based dose ) 1000 mg subject weigh &lt; 75 kg 1200 mg subject weigh ≥75 kg , b.i.d . The duration maintenance phase determine RVR week 8 ( 4 week Telaprevir start . Complete RVR ( measurable HCV-RNA week 8 ) : maintenance week 16 week 48 _Partial RVR ( HCV-RNA 1 000 UI/mL still measurable week 8 ) : maintenance phase week 16 week 48 And stable antiretroviral treatment 3 month among authorized combination : ( tenofovir 300 mg , emtricitabine 200 mg , atazanavir 300 mg , ritonavir 100 mg ) q.d . ( tenofovir 300 mg , emtricitabine 200 mg , efavirenz 600 mg ) q.d . ( tenofovir 300 mg , emtricitabine 200 mg q.d . raltegravir 400 mg b.i.d . ) Drug-Drug interaction data available . Patients could receive one 3 combination include receive stable combination least 3 drug among follow : tenofovir , emtricitabine/lamivudine , efavirenz , atazanavir-boosted , raltegravir ( Drug-Drug interaction data available ) . These patient participate pharmacokinetic study . The trial enroll 80 subject . The proportion patient include , present cirrhosis ( METAVIR F4 ) remain 50 % patient The proportion patient include , null-responders previous HCV treatment ( HCV-RNA decline week 12 less 2 log10 UI/ml ) cirrhosis ( maximum equal METAVIR F3 ) remain 30 % patient .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Informed consent form sign screen visit late Patient register covered social security scheme HIV1 infection Chronic , genotype 1 , hepatitis C detectable HCV RNA screen Virological failure follow previous treatment least 12 week peginterferon alpha2a ≥ 135 µg weekly peginterferon alpha2b ≥ 1.0 µg per kg weekly + ribavirin ≥ 600 mg daily . Virological failure define persistence detectable HCVRNA , genotype . Null responder patient , less 2 Log10 HCVRNA decline week 12 cirrhosis exclude study . Null responder patient without cirrhosis ( equal METAVIR F3 ) limit less 30 % patient include No Interferon and/or Ribavirin within past 6 month Stable antiretroviral treatment 3 month screen . Authorized combination : tenofoviremtricitabineboosted atazanavir , tenofoviremtricitabineefavirenz , tenofoviremtricitabineraltegravir , DrugDrug interaction data available . Patients stable combination least 3 follow drug : tenofovir , emtricitabine/lamivudine , efavirenz , atazanavirboosted , raltegravir . These patient participate pharmacokinetic study CD4 &gt; 200/mm3 &gt; 15 % screen Plasma HIVRNA &lt; 50 copies/mL least 6 month screen visit Body weight ≥ 40 kg equal 125 kg Fibrosis stage document significant liver biopsy ( cumulative length ≥ 15 mm ≥ 6 portal space ) , within 3 year . Patients previous liver biopsy exhibit cirrhosis lesion ( METAVIR F4 ) allow enter study without new biopsy . The proportion patient cirrhosis lesion ( METAVIR F4 ) limit 50 % patient . Male patient , female patient childbearing potency heterosexual partner must use adequate contraception 1 month initiation treatment 7 month follow end treatment men 4 month follow end treatment woman . Subjects ( female partner ) must pregnant plan become pregnant within 2 year enrol study Patient liver failure ( Child B C ) past history decompensated cirrhosis Significant oesophageal varix ( Stages 23 ) gastrointestinal endoscopy within 3 year Detectable AgHBs HIV2 coinfection Contraindication ribavirin peginterferon Severe preexist cardiac pulmonary disease Untreated dysthyroidism Uncontrolled Type 2 diabetes Optic neuritis past history retinal condition History organ transplant Severe hemoglobinopathy Congenital QT prolongation , family history congenital QT prolongation sudden unexpected death Contraindication telaprevir , hypersensitivity component drug product Any disease require long term , systemic corticotherapy immunosuppressive therapy study Alcohol intake may represent obstacle participation subject Substance abuse may represent obstacle participation subject Acute CDC stage C opportunistic infection within previous 6 month Past history cancer within previous 5 year ( except skin basal cell carcinoma , Kaposi 's disease stable remission , situ cervical cancer situ anal cancer ) Any active malignant disease include hepatocellular carcinoma Patients unable observe study procedure Participation another clinical trial within previous 30 day Haemoglobin &lt; 120 g/L woman &lt; 130 g/L men Platelets &lt; 90 000/mm3 Neutrophils &lt; 1 500/mm3 Renal insufficiency define estimate Glomerular Filtration Rate &lt; 60 mL/mn ( MDRD equation ) Associated medication susceptible interfere pharmacokinetic parameter telaprevir and/or antiretroviral associate drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>HIV Infection</keyword>
	<keyword>Telaprevir</keyword>
	<keyword>Peginterferon alfa-2a</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Pharmacogenetic</keyword>
	<keyword>Previous peginterferon-ribavirin regimen failure</keyword>
</DOC>